EUVIMEDEUVIMED entdecken
Open Access

Incidence of serious adverse events caused by tyrosine kinase inhibitor treatment following immune checkpoint inhibitor therapy in advanced NSCLC patients with oncogenic driver alterations

Yukiko Shimoda, Tatsuya Yoshida, Jun Miyakoshi, Masahiro Torasawa, Akiko Tateishi, Yuji Matsumoto, Ken Masuda, Yuki Shinno, Yusuke Okuma, Yasushi Goto, Hidehito Horinouchi, Noboru Yamamoto und 1 weitere

Cancer Immunology, Immunotherapy · 2023

DOI: 10.1007/s00262-023-03429-z ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2023. Verfasst von Yukiko Shimoda und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Sequential tyrosine kinase inhibitors (TKIs) following immune checkpoint inhibitors (ICIs) increases the incidence of serious adverse events (SAEs). However, the factors and the types of TKIs that affect the incidence of SAEs remain unknown. METHODS: We retrospectively reviewed advanced non-small cell lung cancer (NSCLC) patients who received sequential TKIs following ICIs between November 2015 and April 2021. All AEs were evaluated using Common Terminology Criteria for Adverse Events (CTCAE) ver 5.0. RESULTS: Among 1,638 NSCLC patients who received ICIs, 63 patients received sequential TKIs following ICIs. The types of TKIs included EGFR-TKIs in 48 patients, ALK-TKIs in 10 patients, and others in 5 patients. The median dosing interval was 57 days (range: 7-698). Eighteen (28.6%) patients developed SAEs (Grade 3/4 or hospitalized). The incidence of SAEs and withdrawal of TKIs due to AEs were significantly higher in patients (n = 40) who initiated TKI treatment within 3 months after ICIs than in patients (n = 23) who initiated TKI treatment 3 months after ICIs (SAEs, 40.0% vs. 4.3%, p < 0.01; withdrawal rate: 57.5% vs. 21.7%, p < 0.01). There was no significant difference in the incidence of SAEs and withdrawal rate due to AEs between EGFR-TKIs and other TKIs (SAE, 22.9% vs. 40.0%, p = 0.20; withdrawal rate: 41.7% vs. 53.3%, p = 0.55). CONCLUSION: The dosing interval from last ICI to the initiation of TKI treatment can affects the incidence of SAEs and the withdrawal rate due to AEs regardless of the types of TKIs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsAntineoplastic AgentsHumansImmune Checkpoint InhibitorsTyrosine Kinase InhibitorsIncidenceRetrospective StudiesProtein Kinase InhibitorsErbB Receptors

Stichwörter der Autor:innen

Dosing intervalNon-small cell lung cancerSequential therapySerious adverse events

Substanzen

Immune Checkpoint InhibitorsTyrosine Kinase InhibitorsAntineoplastic AgentsProtein Kinase InhibitorsErbB Receptors

Autor:innen und Institutionen

  • Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.
  • Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan. tatyoshi@ncc.go.jp.
  • Department of Experimental Therapeutics, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan. tatyoshi@ncc.go.jp.
  • Department of Experimental Therapeutics, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.

Zitieren

APA

Shimoda, Y., Yoshida, T., Miyakoshi, J., Torasawa, M., Tateishi, A., Matsumoto, Y., Masuda, K., Shinno, Y., Okuma, Y., Goto, Y., Horinouchi, H., Yamamoto, N., & Ohe, Y. (2023). Incidence of serious adverse events caused by tyrosine kinase inhibitor treatment following immune checkpoint inhibitor therapy in advanced NSCLC patients with oncogenic driver alterations. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-023-03429-z

Vancouver

Shimoda Y, Yoshida T, Miyakoshi J, Torasawa M, Tateishi A, Matsumoto Y, et al. Incidence of serious adverse events caused by tyrosine kinase inhibitor treatment following immune checkpoint inhibitor therapy in advanced NSCLC patients with oncogenic driver alterations. Cancer Immunology, Immunotherapy. 2023. doi:10.1007/s00262-023-03429-z

BibTeX
@article{Shimoda2023,
  author = {Shimoda, Yukiko and Yoshida, Tatsuya and Miyakoshi, Jun and Torasawa, Masahiro and Tateishi, Akiko and Matsumoto, Yuji and Masuda, Ken and Shinno, Yuki and Okuma, Yusuke and Goto, Yasushi and Horinouchi, Hidehito and Yamamoto, Noboru and Ohe, Yuichiro},
  title = {Incidence of serious adverse events caused by tyrosine kinase inhibitor treatment following immune checkpoint inhibitor therapy in advanced NSCLC patients with oncogenic driver alterations},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2023},
  doi = {10.1007/s00262-023-03429-z}
}
Kostenlos starten →